California-based AI-driven platform for personalized medicine for cancer care, ImpriMed, celebrates the milestone of serving 4,000 dog blood cancer patients
Mountain View, California - June 14, 2023 --(Newsfile Corp.) - ImpriMed, a leader in precision medicine for pets with blood cancer diseases, announces a significant milestone, having successfully completed 4,000 personalized results for canine blood cancer treatments using their cutting-edge platform. This achievement reflects ImpriMed's commitment to delivering advanced and accessible healthcare solutions to veterinary oncologists and pet parents across the United States.
ImpriMed's flagship product, the Personalized Prediction Profile, has transformed cancer care for dogs with lymphoma and leukemia. Developed with the expertise of board-certified veterinary oncologists, the platform empowers veterinarians to make informed and swift treatment decisions, instilling confidence in the treatment process. By leveraging artificial intelligence (AI) algorithms and a patient's live cancer cell analytics, ImpriMed accurately predicts how a patient will respond to cancer therapy drugs before administering them.
Unlike traditional approaches, ImpriMed's personalized medicine solution is backed by an extensive database of real-world clinical outcomes obtained from canine lymphoma and leukemia patients. The platform combines quantitative high-throughput lab testing with AI, offering healthcare providers a comprehensive drug prediction profile tailored to individual pets. ImpriMed's innovative ex vivo drug sensitivity assay measures how a patient's live tumor cells respond to a panel of anticancer drugs, and in combination with machine learning algorithms trained by real-world clinical outcomes, provides invaluable insights for personalized treatment plans.
ImpriMed's impact on the veterinary oncology space has been significant. Over 200 veterinary oncologists in 30 states have integrated the ImpriMed platform into their practice, helping them deliver personalized treatments to canine lymphoma and leukemia patients. The positive outcomes and testimonials from pet parents and clients further attest to the efficacy of ImpriMed's approach.
Inspired by its success in the veterinary market, ImpriMed is now poised to enter the human oncology space, with plans to introduce its validated platform for human cancer precision medicine. A notable achievement in this regard is the collaboration with one of the most prestigious cancer clinics in the world, where ImpriMed was selected to work with the clinic and gained access to invaluable human data. This recognition serves as a testament to ImpriMed's dedication to advancing precision oncology.
ImpriMed's commitment to innovation is exemplified by its ongoing research and development efforts. They continuously refine their AI models using proprietary databases and incorporate state-of-the-art tumor profiling technologies. By staying at the forefront of technological advancements, ImpriMed aims to continually enhance the accuracy of its predictions and improve the overall quality of its service.
With a global outlook, ImpriMed is expanding its reach beyond the United States. They plan to launch their veterinary services in Europe and APAC. This expansion allows ImpriMed to offer its pioneering solutions to a wider audience, ensuring more pets receive the best possible cancer treatments.
ImpriMed's dedication to pushing boundaries and relentless pursuit of accuracy makes them an invaluable partner for veterinary oncologists and a beacon of hope for pet parents. As they celebrate the milestone of 4,000 patients for dog cancer treatments, ImpriMed remains steadfast in its mission to improve the lives of pets and humans alike through its innovative approach to precision medicine.
Media contact
Name: Mary Ocnean
Email: press@imprimedicine.com
